Minimal Residual Disease 'Coming Soon' As An Approval Endpoint, Celgene Says
Executive Summary
Celgene's ASH briefing notes 'unprecedented' MRD-negative data in Phase I study in multiple myeloma development program for CAR-T therapy bb2121; firm sees potential opportunity for the marker to pave way for approval in earlier-line settings of the disease.
You may also be interested in...
City Of Hope's Joseph Alvarnas On CAR-T Real-World Use, Reimbursement
City of Hope hematologist/oncologist Joseph Alvarnas shares his perspectives on how CAR-T therapies are requiring new models of health care delivery and engagement with more kinds of stakeholders, during an interview at the recent ASH annual meeting.
Janssen Exec On Speeding Earlier Myeloma Interventions To Market With Key Biomarker
Having scored a commercial hit with Darzalex in myeloma, Janssen is looking to speed label expansions to the drug to enable it to intercept earlier in the disease. Janssen R&D executive Craig Tendler explained the importance of addressing smoldering myeloma and of recognizing minimal residual disease as a valid surrogate marker in trials.
FDA Grants Blincyto Accelerated Approval Based On MRD Response Endpoint
Amgen sees the approval as a platform to expand blinatumomab into other hematologic malignancies using similar approaches.